Navigation Links
Appropriate medical screening for antimalarials vital to US military personnel
Date:2/19/2008

Malaria is a constant threat to US military personnel operating in Afghanistan, but some troops may face further risk, as epidemiologists have revealed a significant prevalence of contraindications to the safe use of the anti-malarial drug, mefloquine.

Whilst mefloquine has traditionally been considered an effective prevention for long-term malaria chemoprophylaxis, research reported in the open access publication, Malaria Journal, suggests that US military physicians should ensure careful screening processes prior to prescribing and dispensing the drug. Ignoring such contraindications may lead to an increased incidence of psychiatric and neurological disorders.

An epidemiological study from the US Army Center for Health Promotion and Preventive Medicine, led by Remington Nevin, used military medical surveillance and pharmacosurveillance databases to identify contraindications to mefloquine use among a cohort of 11,725 active duty U.S. military personnel, recently deployed to Afghanistan. The study indicates that 9.6 percent of service members deployed to Afghanistan in early 2007 had evidence of psychiatric, medical or pharmacological contraindications to mefloquine, the primary drug used to protect service members from malaria, which is endemic there. It was also reported that females were twice as likely as males to have a contraindication.

This work underscores the importance of proper systematic screening prior to prescribing and dispensing mefloquine, and the need to provide alternatives to mefloquine suitable for long-term administration among deployed U.S. military personnel.

Mefloquine is generally considered safe when prescribed and dispensed appropriately, and when used as directed. However, this study provides evidence that mefloquine is not a suitable option for a significant number of deploying U.S. servicemembers. This study points to the need for enhanced vigilance during pre-deployment medical screening to ensure the appropriate use of this medication, particularly among females, and underscores the need for continued investment in research and development of alternatives to mefloquine that retain the advantages in compliance of a weekly medication.


'/>"/>

Contact: Charlotte Webber
press@biomedcentral.com
44-020-763-19980
BioMed Central
Source:Eurekalert

Related medicine news :

1. Childhood asthma still inappropriately treated in the UK
2. American Heart Association Surgical Supplement Journal Report: Appropriate Hospital Discharge System Can Prevent Future Cardiac Events
3. Study Finds New Version of QIAGENs HPV Test for Developing Countries Could Reduce Risk of Cervical Cancer by More than Half When Combined With Appropriate Treatment
4. Geriatrician Care Guards Against Risk of Inappropriate Meds
5. Appropriate timing in the use of breast shields in children can further reduce MDCT radiation dose
6. MSU engineering team designs innovative medical device
7. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
8. Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract
9. Owner and Operator of Florida Durable Medical Equipment Company Convicted of Medicare Fraud
10. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
11. Doctors and medical ethicist discuss whether doctors should participate in capital punishment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary ... Work award to iHire in recognition of their exemplary accomplishments in worksite health promotion. ... Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda ... orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including ... accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. ... articles published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. ...
(Date:6/24/2016)... ... , ... National recruitment firm Slone Partners is pleased to announce ... experience, as Vice President of North American Capital Sales at HTG Molecular . ... sales team in the commercialization of the HTG EdgeSeq system and associated reagents in ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... , June 23, 2016 Bracket , a ... its next generation clinical outcomes platform, Bracket eCOA (SM) ... on June 26 – 30, 2016 in Philadelphia ... electronic Clinical Outcome Assessment product of its kind to fully ... Bracket eCOA 6.0 is a flexible platform for ...
Breaking Medicine Technology: